视网膜静脉阻塞的治疗方法的研究
Study on the Treatment of Retinal Vein Occlusion
DOI: 10.12677/acm.2024.1482419, PDF,   
作者: 金 悦:内蒙古科技大学包头医学院,内蒙古 包头;杜红艳:内蒙古自治区人民医院眼科,内蒙古 呼和浩特
关键词: 视网膜静脉阻塞激光光凝术抗血管内皮生长因子药物玻璃体切除术Retinal Vein Occlusion Laser Photocoagulation Anti-Vascular Endothelial Growth Factor Drugs Vitrectomy
摘要: 视网膜静脉阻塞(retinal vein occlusion, RVO)为视网膜血管疾病,是导致视力减退的次要起因。RVO可以根据阻塞的位置分为两种类型:一是(branch retinal vein occlusion, BRVO),即视网膜分支静脉阻塞;二是(central retinal vein occlusion, CRVO),即视网膜中央静脉阻塞。分支静脉阻塞(branch retinal vein occlusion, BRVO)是常见情况,而CRVO则发生在中央静脉位置。如果血流系统存在区域缺血,会被视为缺血性CRVO。黄斑区水肿是CRVO发展中一个重要且严重影响患者视力的并发症,甚至影响日常生活自理能力。目前,现代医学对RVO的治疗多基于发病机制,治疗方法的具体作用靶点明确且迅速见效。然而,目前并无一致的RVO治疗规范,主要西医疗法包括激光光凝、手术和药物治疗。本综述旨在综合RVO治疗方法,为RVO患者诊疗提供更多实用建议。主要探讨RVO的治疗手段,包括激光光凝术、抗VEGF药物及玻璃体切除术。
Abstract: Retinal vein occlusion (RVO) is a retinal vascular disease, which is a secondary cause of visual impairment. RVO can be divided into two types according to the location of obstruction: branch retinal vein occlusion (BRVO), which is branch retinal vein occlusion; the second is central retinal vein occlusion (CRVO), that is, central retinal vein occlusion. Branch retinal vein occlusion (BRVO) is a common condition, while CRVO occurs in the central vein. If there is regional ischemia in the blood flow system, it will be regarded as ischemic CRVO. Macular edema is an important complication in the development of CRVO, which seriously affects the patient’s vision and even affects the ability of daily living. At present, the treatment of RVO in modern medicine is mostly based on the pathogenesis, and the specific targets of treatment are clear and effective. However, there is currently no consistent treatment standard for RVO. The main western medicine therapies include laser photocoagulation, surgery and drug therapy. This review aims to synthesize RVO treatment methods and provide more practical suggestions for the diagnosis and treatment of RVO patients. This article mainly discusses the treatment of RVO, including laser photocoagulation, anti-VEGF drugs and vitrectomy.
文章引用:金悦, 杜红艳. 视网膜静脉阻塞的治疗方法的研究[J]. 临床医学进展, 2024, 14(8): 1771-1775. https://doi.org/10.12677/acm.2024.1482419

参考文献

[1] 顾冉冉, 赵博军. 视网膜静脉阻塞中西医治疗进展[J]. 中西医结合研究, 2021, 13(3): 196-199+202.
[2] 彭涛. 口服与药物注射联合眼底激光治疗糖尿病视网膜病变黄斑水肿疗效及对患者血清VEGF的影响[J]. 饮食保健, 2018 , 5(31): 25-26.
[3] 郑瑜, 沙翔垠, 宋莉. 577nm阈下微脉冲激光治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J]. 中国实用眼科杂志, 2016, 34(5): 439-442.
[4] 周龙芳, 杨红. 同型半胱氨酸与视网膜静脉阻塞关系的临床研究[C]//江苏省第十五次眼科学学术会议暨2014中国眼底病论坛——眼底血管疾病诊断治疗进展专题研讨会论文集. 2014: 11.
[5] 张兰兰. 雷珠单抗联合激光治疗视网膜静脉阻塞继发黄斑水肿患者的效果[J]. 中国民康医学, 2024, 36(10): 53-56.
[6] 四川大学华西医院, 成都华西海圻医药科技有限公司, 国家成都中药安全性评价中心. 一种恒河猴脉络膜血管新生模型的制备方法[P]. CN201010149753.0, 2011-10-19.
[7] 丁振强, 何守志. Ranibizumab治疗湿性AMD的相关研究[J]. 国际眼科杂志, 2007, 7(5): 1396-1399.
[8] 王庆华. 阿瓦斯汀抑制兔眼碱烧伤角膜新生血管的研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2014.
[9] 王军花, 高桂平. Avastin不同给药途径对兔角膜新生血管及超微结构的影响[J]. 眼科新进展, 2012, 32(5): 427-431.
[10] 阮薏蒙, 姚东伟, 施彦. 雷珠单抗联合地塞米松玻璃体内植入剂治疗视网膜静脉阻塞继发黄斑水肿的临床研究[J]. 中国临床药理学杂志, 2023, 39(23): 3397-3400.
[11] Bashshur, Z.F. (2004) Intravitreal Triamcinolone for the Management of Macular Edema Dueto Nonischemic Central Retinal Vein Occlusion. Archives of Ophthalmology, 122, Article 1137. [Google Scholar] [CrossRef] [PubMed]
[12] Anguita, R., Tasiopoulou, A., Shahid, S., Roth, J., Sim, S.Y. and Patel, P.J. (2021) A Review of Aflibercept Treatment for Macular Disease. Ophthalmology and Therapy, 10, 413-428. [Google Scholar] [CrossRef] [PubMed]
[13] Sarwar, S., Clearfield, E., Soliman, M.K., Sadiq, M.A., Baldwin, A.J., Hanout, M., et al. (2016) Aflibercept for Neovascular Age-Related Macular Degeneration. Cochrane Database of Systematic Reviews, 2, CD011346. [Google Scholar] [CrossRef] [PubMed]
[14] 向宛, 王世娟, 唐慧. 康柏西普联合全视网膜激光光凝治疗缺血型视网膜中央静脉阻塞患者的临床研究[J]. 临床医学工程, 2024, 31(3): 257-258.
[15] 董雯佳, 游志鹏, 余晓, 等. 红花黄色素注射液联合抗VEGF药物治疗非缺血性视网膜中央静脉阻塞[J]. 国际眼科杂志, 2023, 23(12): 1954-1960.